Merck & Co., Inc. (NYSE:MRK) Shares Purchased by Stillwater Capital Advisors LLC

Stillwater Capital Advisors LLC boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 1.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 209,366 shares of the company’s stock after acquiring an additional 2,170 shares during the quarter. Merck & Co., Inc. accounts for about 3.5% of Stillwater Capital Advisors LLC’s investment portfolio, making the stock its 7th largest holding. Stillwater Capital Advisors LLC’s holdings in Merck & Co., Inc. were worth $19,088,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of MRK. Gordian Capital Singapore Pte Ltd acquired a new stake in Merck & Co., Inc. during the 4th quarter worth about $154,000. Unigestion Holding SA boosted its position in Merck & Co., Inc. by 37.3% during the 4th quarter. Unigestion Holding SA now owns 160,295 shares of the company’s stock worth $12,285,000 after acquiring an additional 43,530 shares during the period. Jag Capital Management LLC boosted its position in Merck & Co., Inc. by 23.9% during the 4th quarter. Jag Capital Management LLC now owns 14,407 shares of the company’s stock worth $1,104,000 after acquiring an additional 2,783 shares during the period. IHT Wealth Management LLC lifted its holdings in shares of Merck & Co., Inc. by 1.1% during the 4th quarter. IHT Wealth Management LLC now owns 14,131 shares of the company’s stock valued at $1,083,000 after buying an additional 158 shares during the last quarter. Finally, LPL Financial LLC lifted its holdings in shares of Merck & Co., Inc. by 4.0% during the 4th quarter. LPL Financial LLC now owns 1,989,805 shares of the company’s stock valued at $152,499,000 after buying an additional 75,918 shares during the last quarter. 73.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Mizuho assumed coverage on Merck & Co., Inc. in a report on Friday, June 24th. They set a “buy” rating and a $100.00 price target for the company. SVB Leerink lifted their price target on Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a report on Monday, September 12th. Cowen lifted their price target on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a report on Monday, June 27th. Erste Group Bank upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Thursday, August 25th. Finally, Berenberg Bank upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and lifted their price target for the company from $95.00 to $100.00 in a report on Wednesday, September 14th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $98.28.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $87.51 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.39 and a debt-to-equity ratio of 0.66. The business’s 50 day moving average is $88.83 and its two-hundred day moving average is $87.81. The company has a market cap of $221.69 billion, a P/E ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33. Merck & Co., Inc. has a 12 month low of $71.50 and a 12 month high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.67 by $0.20. The company had revenue of $14.59 billion for the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The company’s revenue for the quarter was up 28.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.31 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 7.33 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be given a $0.69 dividend. This represents a $2.76 annualized dividend and a yield of 3.15%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is currently 42.27%.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.